Grifols' Xembify (20% SC Immunoglobulin) Receives FDA's Approval for the Treatment of Primary Immunodeficiencies
Shots:
- The approval of Xembify reflects Grifols’ commitment to R+D+i and innovation which enables the company to develop new therapies and enhances its Bioscience Division’s product portfolio
- Grifol is working with regulatory authorities to seek approval in Canada- Europe and other global markets and plans to launch the Xembify in the US in Q4’19
- Xembify is a 20% SC Ig solution indicated to treat patients with primary humoral immunodeficiency (PI) aged ≥ 2yrs. Additionally- Grifols’ GamaSTAN & HyperRAB has received FDA’s approval in 2018 for providing protection against hepatitis A and measles & to treat patients exposed to rabies virus
Click here to read full press release/ article | Ref: Grifols | Image: The Corner
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
